The ontinuous positive airway pressure breathing machine (CPAP) was used firstly in 1981 by Dr. Sullivan from Australia to treat the sleep apnea syndrome (OSA). The CPAP device has been successfully used since then for its effective treatment of sleep apnea syndrome with safety, less side effects and efficient treatment characteristics. Sleep apnea syndrome is recognized as a slow and invisible killer of life-threatening in the recent 30 years. The syndrome occurs among 4% of population and 20% to 40% in people over 65 ages. Sleep apnea syndrome mailnly features recurrent apnea during sleep causing hypoxia leading to consequences of cardiovascular and cerebrovascular disease, diabetes and other damage to many organs. Almost 80% of drug-resistant hypertension, 50% - 70% of congestive heart failure, nearly 50% of atrial fibrillation and diabetes has relationship with sleep apnea syndrome. CPAP treats the disorder effectively with minimal risk and side effects.